Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Matinas BioPharma Holdings, Inc.
Matinas BioPharma Prices $10 Million Registered Direct Offering
April 03, 2024
From
Matinas BioPharma Holdings, Inc.
Via
GlobeNewswire
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
March 27, 2024
From
Matinas BioPharma Holdings, Inc.
Via
GlobeNewswire
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
March 25, 2024
From
Matinas BioPharma Holdings, Inc.
Via
GlobeNewswire
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards
March 22, 2024
From
Matinas BioPharma Holdings, Inc.
Via
GlobeNewswire
Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution
February 26, 2024
From
Matinas BioPharma Holdings, Inc.
Via
GlobeNewswire
Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
February 20, 2024
From
Matinas BioPharma Holdings, Inc.
Via
GlobeNewswire
Matinas BioPharma to Present at Biotech Showcase 2024
January 03, 2024
From
Matinas BioPharma Holdings, Inc.
Via
GlobeNewswire
Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides
December 27, 2023
From
Matinas BioPharma Holdings, Inc.
Via
GlobeNewswire
Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA
December 21, 2023
From
Matinas BioPharma Holdings, Inc.
Via
GlobeNewswire
Matinas BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business Update
November 08, 2023
From
Matinas BioPharma Holdings, Inc.
Via
GlobeNewswire
Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model
November 07, 2023
From
Matinas BioPharma Holdings, Inc.
Via
GlobeNewswire
Matinas BioPharma to Webcast Conference Call to Discuss Third Quarter 2023 Financial Results and Provide a Business Update on November 8, 2023
November 01, 2023
From
Matinas BioPharma Holdings, Inc.
Via
GlobeNewswire
Patient with Candida krusei Infection in Matinas BioPharma’s Oral MAT2203 Expanded Access Program Achieves Complete Clinical Resolution
October 11, 2023
From
Matinas BioPharma Holdings, Inc.
Via
GlobeNewswire
Matinas BioPharma to Present at Two Investment Conferences in October 2023
September 28, 2023
From
Matinas BioPharma Holdings, Inc.
Via
GlobeNewswire
Matinas BioPharma to Feature MAT2203 in a Pipeline Presentation at IDWeek
September 27, 2023
From
Matinas BioPharma Holdings, Inc.
Via
GlobeNewswire
Matinas BioPharma Announces Notification of NYSE American Continued Listing Deficiency
September 22, 2023
From
Matinas BioPharma Holdings, Inc.
Via
GlobeNewswire
Matinas BioPharma to Participate in the H.C. Wainwright Global Investment Conference
September 06, 2023
From
Matinas BioPharma Holdings, Inc.
Via
GlobeNewswire
Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseases
August 22, 2023
From
Matinas BioPharma Holdings, Inc.
Via
GlobeNewswire
Matinas BioPharma Reports Second Quarter 2023 Financial Results and Provides a Business Update
August 09, 2023
From
Matinas BioPharma Holdings, Inc.
Via
GlobeNewswire
Matinas BioPharma to Participate in the BTIG Virtual Biotechnology Conference 2023
August 02, 2023
From
Matinas BioPharma Holdings, Inc.
Via
GlobeNewswire
Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2023 Financial Results and Provide a Business Update on August 9, 2023
July 26, 2023
From
Matinas BioPharma Holdings, Inc.
Via
GlobeNewswire
Matinas BioPharma to Present at the JMP Securities Life Sciences Conference on May 15, 2023
May 11, 2023
From
Matinas BioPharma Holdings, Inc.
Via
GlobeNewswire
Matinas BioPharma Reports First Quarter 2023 Financial Results and Provides a Business Update
May 10, 2023
From
Matinas BioPharma Holdings, Inc.
Via
GlobeNewswire
Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2023 Financial Results and Provide a Business Update on May 10, 2023
May 03, 2023
From
Matinas BioPharma Holdings, Inc.
Via
GlobeNewswire
Compassionate Use Patient Treated with Matinas BioPharma’s MAT2203 and Showing Complete Clinical Resolution of Rare R. mucilaginosa Fungal Infection Featured in Oral Presentation at ECCMID
April 18, 2023
From
Matinas BioPharma Holdings, Inc.
Via
GlobeNewswire
Matinas BioPharma Reports 2022 Financial Results and Provides a Business Update
March 15, 2023
From
Matinas BioPharma Holdings, Inc.
Via
GlobeNewswire
Matinas BioPharma to Webcast Conference Call to Discuss 2022 Financial Results and Provide a Business Update on March 15, 2023
March 08, 2023
From
Matinas BioPharma Holdings, Inc.
Via
GlobeNewswire
Matinas BioPharma Announces that MAT2203 Will Be Featured in Two Oral Presentations at ECCMID
March 02, 2023
From
Matinas BioPharma Holdings, Inc.
Via
GlobeNewswire
Matinas BioPharma Provides Business Update and 2023 Strategic Outlook
January 30, 2023
From
Matinas BioPharma Holdings, Inc.
Via
GlobeNewswire
Matinas BioPharma to Provide Corporate Update and 2023 Business Outlook on January 30, 2023
January 23, 2023
From
Matinas BioPharma Holdings, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.